We need your help now

Support from readers like you keeps The Journal open.

You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.

If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.


This test means no chemotherapy for some breast cancer patients

The gene test is only available here since 2011.

A STUDY ON a new test for breast cancer shows that it reduces the need for chemotherapy in some patients.

The test, Oncotype DX, involves a sample of the tumour being taken and sent to the US for gene testing. It has only been available in Ireland for four years.

Suitable patients

Patients who are suitable for the test – whose cancer is node negative and hormone positive – have their tumour gene-tested.

The test looks at the activity of 21 genes in this particular breast cancer, and is able to see how the cancer is going to behave into the future and whether it would benefit from chemotherapy or not.

Genomic Health presented 11 studies today in Vienna, Austria, on the test in Ireland.


They include a real-life observational study in Ireland, which demonstrates significant reductions in chemotherapy and cost savings when the test is used in early-stage breast cancer.

Dr Janice Walsh, Consultant Medical Oncologist at St Vincent’s University Hospital in Dublin, led the research project for the All Ireland Co-Operative Oncology Research Group (ICORG) in collaboration with the National Cancer Control Programme (NCCP).

Dr Walsh told that the test has been standard practice in the United States since 2005, but was only introduced in Ireland, following a long campaign, in 2011.

Ireland was the first European market to publicly reimburse the test.

The study at Irish hospitals showed that out of the 583 patients who were included in the analysis, 59% underwent a change in their treatment decision.

339 of the patients would have been recommended chemotherapy had they not undergone the test – the test showed that they could be changed to hormone therapy alone, as chemotherapy would have given them minimal or no benefit.

Dr Walsh said this is “hugely significant” as it means the patients can avoid the side effects from chemotherapy.

It is estimated that there are about 600 eligible patients a year.

Breast cancer is the most frequently diagnosed cancer in Irish women.

Kieran Kenny of Genomic Health said that the test has demonstrated value for patients and the health care system.

Read: ‘My GP just picked up the phone and called the surgeon straight away. I’ll never forget it’>

Readers like you are keeping these stories free for everyone...
A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article. Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation.

Your Voice
Readers Comments
    Submit a report
    Please help us understand how this comment violates our community guidelines.
    Thank you for the feedback
    Your feedback has been sent to our team for review.